These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33390349)

  • 1. Autologous Stem Cell Transplant for Treatment of Multiple Myeloma in a Patient with Concomitant Porphyria Cutanea Tarda.
    Mohamed ZA; Pelletier S; Vintze-Geoffrion A; Lagacé-Nadon S; Olney HJ; Adam JP
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e264-e266. PubMed ID: 33390349
    [No Abstract]   [Full Text] [Related]  

  • 2. Porphyria cutanea tarda in a patient with post-transplant MDS.
    Oubre D; Cruz J; Keung Y
    Bone Marrow Transplant; 2001 Jan; 27(2):219-20. PubMed ID: 11281395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.
    de Tute RM; Rawstron AC; Gregory WM; Child JA; Davies FE; Bell SE; Cook G; Szubert AJ; Drayson MT; Jackson GH; Morgan GJ; Owen RG
    Haematologica; 2016 Feb; 101(2):e69-71. PubMed ID: 26471484
    [No Abstract]   [Full Text] [Related]  

  • 4. [Porphyria cutanea tarda in a child undergoing bone marrow grafting].
    Royer-Bégyn M; Teira P; Deybach JC; Mas E; Mazereeuw-Hautier J
    Ann Dermatol Venereol; 2010 Oct; 137(10):640-4. PubMed ID: 20932445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose chemotherapy and autologous stem cell transplantation for multiple myeloma in HIV-positive patients in the highly active antiretroviral therapy era: the myeloma institute of research and therapy experience.
    Muzaffar J; Usmani S; Abdallah AO; Anaissie E; Cottler-Fox M; Restrepo A
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):171-4. PubMed ID: 23313066
    [No Abstract]   [Full Text] [Related]  

  • 6. Visceral leishmaniasis in a patient with relapsed multiple myeloma receiving high-dose melphalan and autologous stem cell transplant.
    Radujkovic A; Hundemer M; Eisenbach C; Luft T; Penzel R; Goldschmidt H; Ho AD; Bellos F
    Leuk Lymphoma; 2014 Dec; 55(12):2967-9. PubMed ID: 24707945
    [No Abstract]   [Full Text] [Related]  

  • 7. Association between porphyria cutanea tarda and beta-thalassemia major.
    Barbieri L; Macrì A; Lupia Palmieri G; Aurizi C; Biolcati G
    Cell Mol Biol (Noisy-le-grand); 2009 Jul; 55(2):36-9. PubMed ID: 19656449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meningeal Myelomatosis.
    DeFilipp Z; Sahovic EA; Nooka AK
    J Oncol Pract; 2016 Feb; 12(2):187-8. PubMed ID: 26869657
    [No Abstract]   [Full Text] [Related]  

  • 9. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
    Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma.
    Cavo M; Pantani L; Pezzi A; Petrucci MT; Patriarca F; Di Raimondo F; Marzocchi G; Galli M; Montefusco V; Zamagni E; Gamberi B; Tacchetti P; Brioli A; Palumbo A; Sonneveld P
    Leukemia; 2015 Dec; 29(12):2429-31. PubMed ID: 26442610
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.
    Tosi P; Zamagni E; Ronconi S; Benni M; Motta MR; Rizzi S; Tura S; Cavo M
    Leukemia; 2000 Jul; 14(7):1310-3. PubMed ID: 10914557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy.
    Huang W; Li J; Li H; Kang W; Bo J; Zhao Y; Gao C; Zhou D; Yu L
    Leuk Lymphoma; 2012 Dec; 53(12):2507-10. PubMed ID: 22512306
    [No Abstract]   [Full Text] [Related]  

  • 14. Cryptococcal cerebellitis after chemotherapy and autologous stem cell re-infusion in a patient with multiple myeloma.
    Fickweiler W; Aries MJ; Enting RH; Vellenga E; De Keyser J
    J Neurol; 2009 Jan; 256(1):145-6. PubMed ID: 19267173
    [No Abstract]   [Full Text] [Related]  

  • 15. Complete remission following treatment with bortezomib, doxorubicin, dexamethasone and autologous stem cell transplant in patient with immunoglobulin E multiple myeloma.
    Pogłód R; Kraj M; Kruk B; Hagedorna-Tronina R; Łetowska M; Warzocha K
    Leuk Lymphoma; 2010 Dec; 51(12):2291-4. PubMed ID: 20929320
    [No Abstract]   [Full Text] [Related]  

  • 16. Familial and sporadic porphyria cutanea tarda: clinical and biochemical features and risk factors in 152 patients.
    Muñoz-Santos C; Guilabert A; Moreno N; To-Figueras J; Badenas C; Darwich E; Herrero C
    Medicine (Baltimore); 2010 Mar; 89(2):69-74. PubMed ID: 20517178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of hepatitis C virus type 1b in Italian patients with Porphyria cutanea tarda.
    Sampietro M; Fracanzani AL; Corbetta N; Amato M; Mattioli M; Molteni V; Fiorelli G; Fargion S
    Ital J Gastroenterol Hepatol; 1997 Dec; 29(6):543-7. PubMed ID: 9513830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Porphyria cutanea tarda presenting as jaundice].
    Park KH; Park DY; Kim JB; Baek IH; Lee MS; Baik GH; Park SH; Kim JH; Park CK; Kim KH
    Korean J Hepatol; 2004 Dec; 10(4):308-12. PubMed ID: 15613806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should the emphasis be on induction or consolidation therapy in transplant-eligible, newly diagnosed multiple myeloma?
    Krishnan A; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e445-e446. PubMed ID: 32470436
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of autologous stem cell transplantation in the management of multiple myeloma.
    Fermand JP; Brechignac S
    Pathol Biol (Paris); 1999 Feb; 47(2):199-202. PubMed ID: 10192889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.